The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
Jan Cools
Steering Committee Member
Jan Cools is a professor and the head of the Laboratory of Molecular Biology of Leukemia (VIB-KU Leuven), Department of Human Genetics, Leuven, BE. His research priorities include the genetic complexity of ALL. This information is used to develop novel models of leukemia and treatment strategies. Jan has served as a board member of the European Hematology Association (EHA) and has been the editor-in-chief of the open-access journal Haematologica from 2012 to 2017. He is currently editor-in-chief of HemaSphere, EHA’s new open-access hematology journal.
Filter by content: